CU24443B1 - COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC - Google Patents
COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxCInfo
- Publication number
- CU24443B1 CU24443B1 CU2017000084A CU20170084A CU24443B1 CU 24443 B1 CU24443 B1 CU 24443B1 CU 2017000084 A CU2017000084 A CU 2017000084A CU 20170084 A CU20170084 A CU 20170084A CU 24443 B1 CU24443 B1 CU 24443B1
- Authority
- CU
- Cuba
- Prior art keywords
- acid compounds
- hydroxamic acid
- lpxc inhibitors
- isoxazole
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>La presente invención proporciona nuevos compuestos de ácido hidroxámico antibacterianos de fórmula I, los cuales actúan por inhibición de LpxC y son útiles para tratar infecciones bacterianas, especialmente infecciones producidas por bacterias Gram negativas.</p> <p>ESPACIO PARA FÓRMULA<br /> </p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462092402P | 2014-12-16 | 2014-12-16 | |
| PCT/IB2015/059631 WO2016097995A1 (en) | 2014-12-16 | 2015-12-15 | Isoxazole hydroxamic acid compounds as lpxc inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20170084A7 CU20170084A7 (es) | 2017-11-07 |
| CU24443B1 true CU24443B1 (es) | 2019-10-04 |
Family
ID=55025302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2017000084A CU24443B1 (es) | 2014-12-16 | 2015-12-15 | COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC |
Country Status (41)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202432140A (zh) | 2013-05-17 | 2024-08-16 | 美商英塞特控股公司 | 作為jak抑制劑之聯吡唑衍生物 |
| UA123790C2 (uk) * | 2016-06-14 | 2021-06-02 | Новартіс Аг | Кристалічна форма (r)-4-(5-(циклопропілетиніл)ізоксазол-3-іл)-n-гідрокси-2-метил-2-(метилсульфоніл)бутанаміду як антибактеріального агента |
| CN107434766A (zh) * | 2017-08-09 | 2017-12-05 | 凯莱英医药集团（天津）股份有限公司 | 烷烃羟胺类化合物的合成装置及连续合成方法 |
| CN111936135A (zh) | 2018-02-16 | 2020-11-13 | 因赛特公司 | 用于治疗细胞因子相关的病症的jak1通路抑制剂 |
| AU2019383674A1 (en) * | 2018-11-21 | 2021-06-10 | Taisho Pharmaceutical Co., Ltd. | Novel imidazole derivative |
| JP2023528868A (ja) | 2020-06-02 | 2023-07-06 | インサイト・コーポレイション | Ｊａｋ１阻害剤の調製プロセス |
| EP4259131A1 (en) | 2020-12-08 | 2023-10-18 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of vitiligo |
| CN112603936B (zh) * | 2020-12-28 | 2022-08-02 | 仲恺农业工程学院 | 一种抑制气单胞菌属的组合物及其制备方法与应用 |
| US20240150298A1 (en) * | 2021-02-11 | 2024-05-09 | Blacksmith Medicines, Inc. | Antibacterial compounds |
| JP2024507139A (ja) * | 2021-02-11 | 2024-02-16 | ブラックスミス メディシンズ，インク． | 抗菌性化合物 |
| IL311588A (en) * | 2021-09-28 | 2024-05-01 | Blacksmith Medicines Inc | LPXC inhibitors and their uses |
| WO2024067813A1 (zh) * | 2022-09-28 | 2024-04-04 | 浙江海正药业股份有限公司 | 芳香乙炔类衍生物及其制备方法和其医药上的用途 |
| WO2024067812A1 (zh) * | 2022-09-28 | 2024-04-04 | 浙江海正药业股份有限公司 | 芳香乙炔类衍生物及其制备方法和用途 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3381783D1 (de) | 1982-03-03 | 1990-09-13 | Genentech Inc | Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen. |
| EP0418667B1 (de) | 1989-09-22 | 1995-08-16 | BASF Aktiengesellschaft | Carbonsäureamide |
| JP4440344B2 (ja) | 1996-08-16 | 2010-03-24 | シェーリング コーポレイション | 哺乳動物細胞表面抗原；関連試薬 |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| EP1025228A4 (en) | 1997-10-21 | 2002-09-18 | Human Genome Sciences Inc | HUMAN PROTEIN TR11, TR11SV1 AND TR11SV2 SIMILAR TO THE TUMOR NECROSIS FACTOR RECEPTOR |
| EP1053321A1 (en) | 1998-02-09 | 2000-11-22 | Genentech, Inc. | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
| DE60036945T2 (de) | 1999-07-12 | 2008-08-21 | Genentech, Inc., South San Francisco | Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen |
| CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| MXPA05007394A (es) | 2003-01-08 | 2005-09-12 | Chiron Corp | Agentes antibacterianos. |
| EP1631260A2 (en) | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AU2004244626A1 (en) | 2003-05-23 | 2004-12-09 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GITR ligand and GITR ligand-related molecules and antibodies and uses thereof |
| US20050048054A1 (en) | 2003-07-11 | 2005-03-03 | Shino Hanabuchi | Lymphocytes; methods |
| JP2007518399A (ja) | 2003-12-02 | 2007-07-12 | ジェンザイム コーポレイション | 肺癌を診断および治療する組成物並びに方法 |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| WO2006083289A2 (en) | 2004-06-04 | 2006-08-10 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| GB0502418D0 (en) | 2005-02-05 | 2005-03-16 | Astrazeneca Ab | Compounds |
| EP1866339B8 (en) | 2005-03-25 | 2021-12-01 | GITR, Inc. | Gitr binding molecules and uses therefor |
| JP4361545B2 (ja) | 2005-05-09 | 2009-11-11 | 小野薬品工業株式会社 | ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法 |
| RS54271B1 (en) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1) |
| WO2007133822A1 (en) | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Gitr antibodies for the treatment of cancer |
| ES2616355T3 (es) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor humano de muerte programada PD-1 |
| JP5932217B2 (ja) | 2007-07-12 | 2016-06-08 | ジーアイティーアール， インコーポレイテッド | Ｇｉｔｒ結合分子を使用する併用療法 |
| AU2009213738B2 (en) | 2008-02-11 | 2015-01-22 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| EA201170031A1 (ru) | 2008-07-02 | 2011-08-30 | Эмерджент Продакт Дивелопмент Сиэтл, Ллс | СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ ПО ОТНОШЕНИЮ К TGF-β |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EA201170375A1 (ru) | 2008-08-25 | 2012-03-30 | Эмплиммьюн, Инк. | Антагонисты pd-1 и способы их применения |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| US8586023B2 (en) | 2008-09-12 | 2013-11-19 | Mie University | Cell capable of expressing exogenous GITR ligand |
| JP5524215B2 (ja) * | 2008-09-19 | 2014-06-18 | ファイザー・インク | 抗菌剤として有用なヒドロキサム酸誘導体 |
| HRP20240240T1 (hr) | 2008-12-09 | 2024-04-26 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| ES2629337T3 (es) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
| LT3023438T (lt) | 2009-09-03 | 2020-05-11 | Merck Sharp & Dohme Corp. | Anti-gitr antikūnai |
| WO2011045703A2 (en) * | 2009-10-13 | 2011-04-21 | Pfizer Inc. | C-linked hydroxamic acid derivatives useful as antibacterial agents |
| GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| CA2899583A1 (en) | 2009-12-16 | 2011-06-23 | Pfizer Inc. | N-linked hydroxamic acid derivatives useful as antibacterial agents |
| AU2010343056A1 (en) | 2009-12-29 | 2012-08-02 | Emergent Product Development Seattle, Llc | Ron binding constructs and methods of use thereof |
| US8877754B2 (en) | 2010-09-06 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| TW201249786A (en) | 2010-11-10 | 2012-12-16 | Achaogen Inc | Antibacterial agents |
| MA34963B1 (fr) | 2011-03-07 | 2014-03-01 | Pfizer | Derives de fluoro-pyridinone utiles en tant qu'agents antibacteriens |
| US8809333B2 (en) * | 2011-04-08 | 2014-08-19 | Pfizer Inc. | Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents |
| CN103717582B (zh) * | 2011-04-08 | 2015-09-30 | 辉瑞大药厂 | 用作抗菌剂的异*唑衍生物 |
| WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
| CA2856895C (en) | 2011-11-28 | 2021-10-26 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| WO2014160649A1 (en) | 2013-03-29 | 2014-10-02 | Novartis Ag | Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections |
-
2015
- 2015-12-15 CU CU2017000084A patent/CU24443B1/es unknown
- 2015-12-15 AU AU2015365455A patent/AU2015365455B2/en not_active Ceased
- 2015-12-15 SG SG11201704053WA patent/SG11201704053WA/en unknown
- 2015-12-15 WO PCT/IB2015/059631 patent/WO2016097995A1/en active Application Filing
- 2015-12-15 BR BR112017011422-4A patent/BR112017011422A2/pt not_active IP Right Cessation
- 2015-12-15 TN TN2017000207A patent/TN2017000207A1/en unknown
- 2015-12-15 MX MX2017007980A patent/MX2017007980A/es active IP Right Grant
- 2015-12-15 PT PT158168930T patent/PT3233843T/pt unknown
- 2015-12-15 JP JP2017532143A patent/JP6697466B2/ja not_active Expired - Fee Related
- 2015-12-15 EA EA201791353A patent/EA032138B1/ru not_active IP Right Cessation
- 2015-12-15 PL PL15816893T patent/PL3233843T3/pl unknown
- 2015-12-15 CR CR20170260A patent/CR20170260A/es unknown
- 2015-12-15 EP EP15816893.0A patent/EP3233843B1/en active Active
- 2015-12-15 RS RS20191403A patent/RS59507B1/sr unknown
- 2015-12-15 SI SI201530987T patent/SI3233843T1/sl unknown
- 2015-12-15 MA MA41185A patent/MA41185B1/fr unknown
- 2015-12-15 UA UAA201705042A patent/UA121225C2/uk unknown
- 2015-12-15 LT LT15816893T patent/LT3233843T/lt unknown
- 2015-12-15 US US14/969,930 patent/US9549916B2/en active Active
- 2015-12-15 KR KR1020177016102A patent/KR20170094214A/ko not_active Application Discontinuation
- 2015-12-15 PE PE2017001078A patent/PE20171044A1/es unknown
- 2015-12-15 CN CN201580066726.8A patent/CN107001295B/zh not_active Expired - Fee Related
- 2015-12-15 ME MEP-2019-305A patent/ME03546B/me unknown
- 2015-12-15 ES ES15816893T patent/ES2756300T3/es active Active
- 2015-12-15 HU HUE15816893A patent/HUE047225T2/hu unknown
- 2015-12-15 MY MYPI2017701741A patent/MY195743A/en unknown
- 2015-12-15 TW TW104142164A patent/TWI693215B/zh not_active IP Right Cessation
- 2015-12-15 CA CA2969803A patent/CA2969803A1/en not_active Abandoned
- 2015-12-15 DK DK15816893T patent/DK3233843T3/da active
- 2015-12-16 UY UY0001036448A patent/UY36448A/es not_active Application Discontinuation
- 2015-12-16 AR ARP150104119A patent/AR107428A1/es unknown
- 2015-12-16 JO JOP/2015/0318A patent/JO3818B1/ar active
-
2016
- 2016-12-12 US US15/375,560 patent/US9815804B2/en active Active
-
2017
- 2017-05-18 IL IL25237317A patent/IL252373B/en active IP Right Grant
- 2017-06-01 PH PH12017501019A patent/PH12017501019B1/en unknown
- 2017-06-08 CL CL2017001460A patent/CL2017001460A1/es unknown
- 2017-06-14 CO CONC2017/0005870A patent/CO2017005870A2/es unknown
- 2017-06-16 SV SV2017005462A patent/SV2017005462A/es unknown
- 2017-06-16 GT GT201700132A patent/GT201700132A/es unknown
- 2017-07-16 EC ECIEPI201745737A patent/ECSP17045737A/es unknown
- 2017-10-09 US US15/728,351 patent/US10029994B2/en active Active
-
2019
- 2019-11-06 HR HRP20192009TT patent/HRP20192009T1/hr unknown
- 2019-11-11 CY CY20191101181T patent/CY1122305T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24443B1 (es) | COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC | |
| CU24441B1 (es) | Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas | |
| EA201391072A1 (ru) | Производные фтор-пиридинона, полезные в качестве антибактериальных агентов | |
| NZ724798A (en) | Polymyxin derivatives as antimicrobial compounds | |
| MX2013011526A (es) | Derivados de isoxazol utiles como agentes antibacteriales . | |
| BR112017011980A2 (pt) | composto, composição farmacêutica, e, método para tratar uma infecção bacteriana. | |
| MX2017012073A (es) | Compuestos de minociclina para biodefensas. | |
| CL2017000484A1 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| EA201790464A1 (ru) | Гетеробициклические соединения и их применение для лечения туберкулеза | |
| BR112018011670A2 (pt) | compostos antibacterianos | |
| PH12016501532A1 (en) | Antibacterial combinations comprising polymyxin | |
| CO2019001995A2 (es) | Inhibidores de beta-lactamasa | |
| EA201590331A1 (ru) | Новые антибактериальные соединения | |
| JO3477B1 (ar) | مركبات أحادي باكتام عضوية لعلاج العدوى البكتيرية | |
| CR20160412A (es) | Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas |